Linking atherosclerosis to Alzheimer's disease: Focus on biomarkers

Frontiers in Bioscience - Elite

Volumn 4 E, Issue 2, 2012, Pages 700-710

  Emanuele, Enzo ^a   Martinelli, Valentina ^a   Abbiati, Vera ^a   Ricevuti, Giovanni ^a,b  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Alzheimer's disease; Atherosclerosis; Biomarkers; Plasma; Review; Serum

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINE OXIDASE (COPPER CONTAINING); APOLIPOPROTEIN A; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYSTATIN C; HOMOCYSTEINE; LIPOPROTEIN A; OSTEOPROTEGERIN; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR;

ALZHEIMER DISEASE; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; CONCENTRATION (PARAMETERS); DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; HEART FAILURE; HUMAN; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; RISK ASSESSMENT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; METABOLISM; REVIEW;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CYSTATIN C; HOMOCYSTEINE; HUMANS; LIPOPROTEIN(A); OSTEOPROTEGERIN; RECEPTORS, IMMUNOLOGIC;

EID: 84860849913     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: 10.2741/e411     Document Type: Article

References (114)

1. R. L. Nussbaum and C. E. Ellis: Alzheimer's disease and Parkinson's disease. N Engl J Med, 348(14), 1356-64 (2003)
2. A. Burns, E. J. Byrne and K. Maurer: Alzheimer's disease. Lancet, 360(9327), 163-5 (2002)
3. R. Altman and J. C. Rutledge: The vascular contribution to Alzheimer's disease. Clin Sci (Lond), 119(10), 407-21 (2010)
4. R.D. Bell and B. V. Zlokovic: Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol, 118(1), 103-13 (2009)
5. B. V. Zlokovic: Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci, 28(4), 202-8 (2005)
6. S. Vasto, G. Candore, G. Duro, D. Lio, M. P. Grimaldi and C. Caruso: Alzheimer's disease and genetics of inflammation: a pharmacogenomic vision. Pharmacogenomics, 8(12), 1735-45 (2007)
7. G. Candore, C. R. Balistreri, M. P. Grimaldi, S. Vasto, F. Listì, M. Chiappelli, F. Licastro, D. Lio and C. Caruso: Age-related inflammatory diseases: role of genetics and gender in the pathophysiology of Alzheimer's disease. Ann N Y Acad Sci, 1089, 472-86 (2006)
8. J.C. de la Torre: Vascular risk factor detection and control may prevent Alzheimer's disease. Ageing Res Rev, 9(3), 218-25 (2010)
9. J.C. de la Torre: The vascular hypothesis of Alzheimer's disease: bench to bedside and beyond. Neurodegener Dis, 7(1-3), 116-21 (2010)
10. S.A. Ligthart, E. P. Moll van Charante, W. A. Van Gool and E. Richard: Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review. Vasc Health Risk Manag, 6, 775-85 (2010)
11. T.C. de Toledo Ferraz Alves, L. K. Ferreira, M. Wajngarten and G. F. Busatto: Cardiac disorders as risk factors for Alzheimer's disease. J Alzheimers Dis, 20(3), 749-63 (2010)
12. T.G. Beach, J. R. Wilson, L. I. Sue, A. Newell, M. Poston, R. Cisneros, Y. Pandya, C. Esh, D. J. Connor, M. Sabbagh, D. G. Walker and A. E. Roher: Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol, 113(1), 13-21 (2007)
13. L. S. Honig, W. Kukull and R. Mayeux: Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology, 64(3), 494-500 (2005)
14. C. Qiu, W. Xu, B. Winblad and L. Fratiglioni: Vascular risk profiles for dementia and Alzheimer's disease in very old people: a population-based longitudinal study. J Alzheimers Dis, 20(1), 293-300 (2010)
15. D. F. Cechetto, V. Hachinski and S. N. Whitehead: Vascular risk factors and Alzheimer's disease. Expert Rev Neurother, 8(5), 743-50 (2008)
16. M. Ewers, M. M. Mielke and H. Hampel: Blood-based biomarkers of microvascular pathology in Alzheimer's disease. Exp Gerontol, 45(1), 75-9 (2010)
17. K. Blennow, H. Hampel, M. Weiner and H. Zetterberg: Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol, 6(3), 131-44 (2010)
18. R.R. Packard and P. Libby: Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem, 54(1), 24-38 (2008)
19. W. Zhou, H. Chai, R. Ding and H. Y. Lam: Distribution of inflammatory mediators in carotid and femoral plaques. J Am Coll Surg, 211(1), 92-8 (2010)
20. J. M. Noble, J. J. Manly, N. Schupf, M. X. Tang, R. Mayeux and J. A. Luchsinger: Association of C-reactive protein with cognitive impairment. Arch Neurol, 67(1), 87-92, (2010)
21. D. Conen and P. M. Ridker: Clinical significance of high-sensitivity C-reactive protein in cardiovascular disease. Biomark Med, 1(2), 229-41 (2007)
22. S. Mora, K. Musunuru and R. S. Blumenthal: The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines. Clin Chem, 55(2), 219-28 (2009)
23. E. T. Yeh: High-sensitivity C-reactive protein as a risk assessment tool for cardiovascular disease. Clin Cardiol, 28(9), 408-12 (2005)
24. A. Mancinella, M. Mancinella, G. Carpinteri, A. Bellomo, C. Fossati, V. Gianturco, A. Iori, E. Ettorre, G. Troisi and V. Marigliano: Is there a relationship between high C-reactive protein (CRP) levels and dementia? Arch Gerontol Geriatr, 49 Suppl 1, 185-94 (2009)
25. A. Schuitemaker, M. G. Dik, R. Veerhuis, P. Scheltens, N. S. Schoonenboom, C. E. Hack, M.A. Blankenstein and C. Jonker: Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiol Aging, 30(11), 1885-9 (2009)
26. K. Nilsson, L. Gustafson and B. Hultberg: C-reactive protein: vascular risk marker in elderly patients with mental illness. Dement Geriatr Cogn Disord, 26(3), 251-6 (2008)
27. S. E. O'Bryant, S. C. Waring, V. Hobson, J. R. Hall, C. B. Moore, T. Bottiglieri, P. Massman and R. Diaz-Arrastia: Decreased C-reactive protein levels in Alzheimer disease. J Geriatr Psychiatry Neurol, 23(1), 49-53 (2010)
28. J. Sundelöf, L. Kilander, J. Helmersson, A. Larsson, E. Rönnemaa, M. Degerman-Gunnarsson, H. Basun, L. Lannfelt and S. Basu: Systemic inflammation and the risk of Alzheimer's disease and dementia: a prospective population-based study. J Alzheimers Dis, 18(1), 79-87 (2009)
29. T. L. Gruenewald, S. Cohen, K. A. Matthews, R. Tracy and T. E. Seeman: Association of socioeconomic status with inflammation markers in black and white men and women in the Coronary Artery Risk Development in Young Adults (CARDIA) study. Soc Sci Med, 69(3), 451-9 (2009)
30. W. Schumacher, J. Cockcroft, N. H. Timpson, C. M. McEniery, J. Gallacher, A. Rumley, G. Lowe, G. D. Smith, I. B. Wilkinson and Y. Ben-Shlomo: Association between C-reactive protein genotype, circulating levels, and aortic pulse wave velocity. Hypertension, 53(2), 150-7 (2009)
31. R. Ientile, M. Currò, N. Ferlazzo, S. Condello, D. Caccamo and F. Pisani: Homocysteine, vitamin determinants and neurological diseases. Front Biosci (Schol Ed), 2, 359-72 (2010)
32. M. N. Di Minno, E. Tremoli, A. Coppola, R. Lupoli and G. Di Minno: Homocysteine and arterial thrombosis: Challenge and opportunity. Thromb Haemost, 103, 942-61 (2010)
33. A. S. Wierzbicki: Homocysteine and cardiovascular disease: a review of the evidence. Diab Vasc Dis Res, 4(2),143-50 (2007)
34. K. T. Williams and K. L. Schalinske: Homocysteine metabolism and its relation to health and disease. Biofactors, 36(1), 19-24 (2010)
35. T. B. Shea, J. Lyons-Weiler and E. Rogers: Homocysteine, folate deprivation and Alzheimer neuropathology. J Alzheimers Dis, 4(4), 261-7 (2002)
36. M. P. Mattson and T. B. Shea: Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci, 26, 137-46 (2003)
37. G. Gorgone, F. Ursini, C. Altamura, F. Bressi, M. Tombini, G. Curcio, P. Chiovenda, R. Squitti, M. Silvestrini, R. Ientile, F. Pisani, P.M. Rossini and F. Vernieri: Hyperhomocysteinemia, intima-media thickness and C677T MTHFR gene polymorphism: a correlation study in patients with cognitive impairment. Atherosclerosis, 206(1), 309-13 (2009)
38. J.F. Cascalheira, S. S. João, S. S. Pinhanços, R. Castro, M. Palmeira, S. Almeida, M. C. Faria and F. C. Domingues: Serum homocysteine: interplay with other circulating and genetic factors in association to Alzheimer's type dementia. Clin Biochem, 42(9), 783-90 (2009)
39. M. Kivipelto, S. Annerbo, J. Hultdin, L. Bäckman, M. Viitanen, L. Fratiglioni and J. Lökk: Homocysteine and holo-transcobalamin and the risk of dementia and Alzheimers disease: a prospective study. Eur J Neurol, 16(7), 808-13 (2009)
40. B. Hooshmand, A. Solomon, I. Kåreholt, J. Leiviskä, M. Rusanen, S. Ahtiluoto, B. Winblad, T. Laatikainen, H. Soininen and M. Kivipelto: Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. Neurology, 75(16), 1408-14 (2010)
41. G. Davis, N. Baboolal, S. Nayak and A. McRae: Sialic acid, homocysteine and CRP: potential markers for dementia. Neurosci Lett, 465(3), 282-4 (2009)
42. I.A. van Rossum, S. Vos, R. Handels and P.J. Visser: Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. J Alzheimers Dis, 20(3), 881-91 (2010)
43. J. Siuda, A. Gorzkowska, M. Patalong-Ogiewa, E. Krzystanek, E. Czech, B. Wiechuła, W. Garczorz, A. Danch, B. Jasińska-Myga and G. Opala: From mild cognitive impairment to Alzheimer's disease - influence of homocysteine, vitamin B12 and folate on cognition over time: results from one-year follow-up. Neurol Neurochir Pol, 43(4), 321-9 (2009)
44. H. McNulty, K. Pentieva, L. Hoey and M. Ward: Homocysteine, B-vitamins and CVD. Proc Nutr Soc, 67(2), 232-7 (2008)
45. K. Miyaki: Genetic polymorphisms in homocysteine metabolism and response to folate intake: a comprehensive strategy to elucidate useful genetic information. J Epidemiol, 20(4), 266-70 (2010)
46. A. McCampbell, K. Wessner, M. W. Marlatt, C. Wolffe, D. Toolan, A. Podtelezhnikov, S. Yeh, R. Zhang, P. Szczerba, K. Q. Tanis, J. Majercak, W. J. Ray and M. Savage: Induction of Alzheimer's-like changes in brain of mice expressing mutant APP fed excess methionine. J Neurochem, 116(1), 82-92 (2011)
47. A. Viswanathan, S. Raj, S. M. Greenberg, M. Stampfer, S. Campbell, B. T. Hyman and M. C. Irizarry: Plasma Abeta, homocysteine, and cognition: the Vitamin Intervention for Stroke Prevention (VISP) trial. Neurology, 72(3), 268-72 (2009)
48. M. Mussap and M. Plebani: Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci, 41(5-6), 467-550 (2004)
49. E. Bengtsson, J. Nilsson and S. Jovinge: Cystatin C and cathepsins in cardiovascular disease. Front Biosci, 13, 5780-6 (2008)
50. J. Liu, G.K. Sukhova, J. S. Sun, W. H. Xu, P. Libby and G.P. Shi: Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol, 24(8), 1359-66 (2004)
51. P. Muntner, D. Mann, J. Winston, S. Bansilal and M. E. Farkouh: Serum cystatin C and increased coronary heart disease prevalence in US adults without chronic kidney disease. Am J Cardiol, 102(1), 54-7(2008)
52. S. Gauthier, G. Kaur, W. Mi, B. Tizon and E. Levy: Protective mechanisms by cystatin C in neurodegenerative diseases. Front Biosci (Schol Ed), 3, 541-54 (2011)
53. A. Nagai, M. Terashima, A. M. Sheikh, Y. Notsu, K. Shimode, S. Yamaguchi, S. Kobayashi, S. U. Kim and J. Masuda: Involvement of cystatin C in pathophysiology of CNS diseases. Front Biosci, 13, 3470-9 (2008)
54. P. Taupin, J. Ray, W. H. Fischer, S. T. Suhr, K. Hakansson, A. Grubb and F. H. Gage: FGF-2-responsive neural stem cell proliferation requires CCg, a novel autocrine/paracrine cofactor. Neuron, 28(2), 385-97 (2000)
55. B. Tizon, E. M. Ribe, W. Mi, C. M. Troy and E. Levy: Cystatin C protects neuronal cells from amyloid-betainduced toxicity. J Alzheimers Dis, 19(3), 885-94 (2010)
56. L.J. Chuo, W. H. Sheu, M. C. Pai and Y. M. Kuo: Genotype and plasma concentration of cystatin C in patients with late-onset alzheimer disease. Dement Geriatr Cogn Disord, 23(4), 251-7 (2007)
57. R. Ghidoni, L. Benussi, M. Glionna, S. Desenzani, V. Albertini, E. Levy, E. Emanuele and G. Binetti: Plasma cystatin C and risk of developing Alzheimer's disease in subjects with mild cognitive impairment. J Alzheimers Dis, 22(3), 985-91 (2010)
58. J. Sundelöf, J. Arnlöv, E. Ingelsson, J. Sundström, S. Basu, B. Zethelius, A. Larsson, M. C. Irizarry, V. Giedraitis, E. Rönnemaa, M. Degerman-Gunnarsson, B. T. Hyman, H. Basun, L. Kilander and L. Lannfelt: Serum cystatin C and the risk of Alzheimer disease in elderly men. Neurology, 71(14), 1072-9 (2008)
59. K. Yaffe, K. Lindquist, M. G. Shlipak, E. Simonsick, L. Fried, C. Rosano, S. Satterfield, H. Atkinson, B. G. Windham and M. Kurella-Tamura: Cystatin C as a marker of cognitive function in elders: findings from the health ABC study. Ann Neurol, 63(6), 798-802 (2008)
60. E. Marrer and F. Dieterle: Impact of biomarker development on drug safety assessment. Toxicol Appl Pharmacol, 243(2):167-79 (2010)
61. F. Galvano, M. Malaguarnera, M. Vacante, M. Motta, C. Russo, G. Malaguarnera, N. D'Orazio and L. Malaguarnera: The physiopathology of lipoprotein (a). Front Biosci (Schol Ed), 2, 866-75 (2010)
62. S. Erqou, A. Thompson, E. Di Angelantonio, D. Saleheen, S. Kaptoge, S. Marcovina and J. Danesh: Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol, 55(19), 2160-7(2010)
63. E. Emanuele, E. Peros, C. Tomaino, E. Feudatari, L. Bernardi, G. Binetti, R. Maletta, A. D'Angelo, L. Montagna, A. C. Bruni and D. Geroldi: Apolipoprotein(a) null phenotype is related to a delayed age at onset of Alzheimer's disease. Neurosci Lett, 357(1), 45-8 (2004)
64. W. Discepolo, T. Wun and L. Berglund: Lipoprotein(a) and thrombocytes: potential mechanisms underlying cardiovascular risk. Pathophysiol Haemost Thromb, 35(3-4), 314-21 (2006)
65. A. D'Angelo, D. Geroldi, M. A. Hancock, V. Valtulina, A. I. Cornaglia, C. A. Spencer, E. Emanuele, A. Calligaro, M. L. Koschinsky, P. Speziale and L. Visai: The apolipoprotein(a) component of lipoprotein(a) mediates binding to laminin: contribution to selective retention of lipoprotein(a) in atherosclerotic lesions. Biochim Biophys Acta, 1687(1-3), 1-10 (2005)
66. V. Bermúdez, N. Arráiz, D. Aparicio, E. Rojas, D. Gotera, X. Guerra, R. Canelón, J. Faría, L. Sorell, A. Amell, N. Reyna, M. Cabrera, E. Mengual, R. Cano, C. Cano and M. Velasco: Lipoprotein(a): from molecules to therapeutics. Am J Ther, 17(3), 263-73 (2010)
67. E. Anuurad, M. B. Boffa, M. L. Koschinsky and L. Berglund L: Lipoprotein(a): a unique risk factor for cardiovascular disease. Clin Lab Med, 26(4), 751-72 (2006)
68. E. Emanuele, E. Peros, C. Tomaino, E. Feudatari, L. Bernardi, G. Binetti, R. Maletta, G. Micieli, A. C. Bruni and D. Geroldi D: Relation of apolipoprotein(a) size to alzheimer's disease and vascular dementia. Dement Geriatr Cogn Disord, 18(2), 189-96 (2004)
69. E. Emanuele, E. Peros, C. Tomaino, E. Feudatari, L. Bernardi, G. Binetti, R. Maletta, G. Micieli, A. C. Bruni and D. Geroldi; Association between small apolipoprotein(a) isoforms and frontotemporal dementia in humans. Neurosci Lett, 353(3), 201-4 (2003)
70. V. Mooser, N. Helbecque, J. Miklossy, S. M. Marcovina, P. Nicod and P. Amouyel: Interactions between apolipoprotein E and apolipoprotein(a) in patients with late-onset alzheimer disease. Ann Intern Med, 132(7), 533-7 (2000)
71. V. Solfrizzi, F. Panza, A. D'Introno, A. M. Colacicco, C. Capurso, A. M. Basile and A. Capurso: Lipoprotein(a), apolipoprotein E genotype, and risk of Alzheimer's disease. J Neurol Neurosurg Psychiatry, 72(6), 732-6 (2002)
72. K. Urakami, K. Wada-Isoe, Y. Wakutani, K. Ikeda, Y. Ji, K. Yamagata, H. Kowa, A. Okada, Y. Adachi and K. Nakashima: Lipoprotein(a) phenotypes in patients with vascular dementia. Dement Geriatr Cogn Disord, 11(3), 135-8. (2000)
73. C. Gazzaruso, A. Garzaniti, P. Buscaglia, G. Bonetti, C. Falcone, P. Fratino, G. Finardi and D. Geroldi: Association between apolipoprotein(a) phenotypes and coronary heart disease at a young age. J Am Coll Cardiol, 33(1), 157-63 (1999)
74. P. Alexiou, M. Chatzopoulou, K. Pegklidou and V. J. Demopoulos : RAGE: a multi-ligand receptor unveiling novel insights in health and disease. Curr Med Chem, 17(21), 2232-52 (2010)
75. A.Z. Kalea, A. M. Schmidt and B. I. Hudson: RAGE: a novel biological and genetic marker for vascular disease. Clin Sci (Lond), 116(8), 621-37 (2009)
76. S.F. Yan, Y. Naka, B. I. Hudson, K. Herold, S. D. Yan, R. Ramasamy and A. M. Schmidt: The ligand/RAGE axis: lighting the fuse and igniting vascular stress. Curr Atheroscler Rep, 8(3), 232-9 (2006)
77. S. Yamagishi and T. Matsui: Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci (Elite Ed), 2, 1184-95 (2010)
78. S. F. Yan, R. Ramasamy and A. M. Schmidt: Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol, 79(10), 1379-86 (2010)
79. C. Falcone, E. Emanuele, A. D'Angelo, M. P. Buzzi, C. Belvito, M. Cuccia and D. Geroldi: Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol, 25(5), 1032-7 (2005)
80. D. Geroldi, C. Falcone and E. Emanuele: Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem, 13(17), 1971-8 (2006)
81. F. Santilli, N. Vazzana, L. G. Bucciarelli and G. Davì: Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr Med Chem, 16(8), 940-52 (2009)
82. E. Leclerc, E. Sturchler, S. W. Vetter and C. W. Heizmann: Crosstalk between calcium, amyloid beta and the receptor for advanced glycation endproducts in Alzheimer's disease. Rev Neurosci, 20(2), 95-110 (2009)
83. A. M. Schmidt, B. Sahagan, R. B. Nelson, J. Selmer, R. Rothlein and J. M. Bell: The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease. Curr Opin Investig Drugs, 10(7), 672-80 (2009)
84. M. O. Chaney, W. B. Stine, T. A. Kokjohn, Y. M. Kuo, C. Esh, A. Rahman, D. C. Luehrs, A. M. Schmidt, D. Stern, S. D. Yan and A. E. Roher: RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling. Biochim Biophys Acta, 1741(1-2), 199-205 (2005)
85. E. Emanuele, A. D'Angelo, C. Tomaino, G. Binetti, R. Ghidoni, P. Politi, L. Bernardi, R. Maletta, A. C. Bruni and G. Geroldi: Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol, 62(11), 1734-6 (2005)
86. R. Ghidoni, L. Benussi, M. Glionna, M. Franzoni, D. Geroldi, E. Emanuele and G. Binetti: Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment. J Neural Transm, 115(7), 1047-50 (2008)
87. K. Li, D. Dai, B. Zhao, L. Yao, S. Yao, B. Wang and Z. Yang: Association between the RAGE G82S polymorphism and Alzheimer's disease. J Neural Transm, 117(1), 97-104 (2010)
88. A. Hernanz, M. De la Fuente, M. Navarro and A. Frank: Plasma aminothiol compounds, but not serum tumor necrosis factor receptor II and soluble receptor for advanced glycation end products, are related to the cognitive impairment in Alzheimer's disease and mild cognitive impairment patients. Neuroimmunomodulation, 14(3-4), 163-7 (2007)
89. F. Fang, L. F. Lue, S. Yan, H. Xu, J. S. Luddy, D. Chen, D. G. Walker, D. M. Stern, S. Yan, A. M. Schmidt, J. X. Chen and S. S. Yan: RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J, 24(4), 1043-55 (2010)
90. Y. Jang, J. Y. Kim, S. M. Kang, J. S. Kim, J. S. Chae, O. Y. Kim, S. J. Koh, H. C. Lee, C. W. Ahn, Y. D. Song and J. H. Lee: Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans. Metabolism, 56(2), 199-205 (2007)
91. P. Reid and I. Holen: Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol, 88(1), 1-17 (2009)
92. P. D'Amelio, G. Isaia and G. C. Isaia: The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. J Endocrinol Invest, 32(4 Suppl), 6-9 (2009)
93. S. M. Venuraju, A. Yerramasu, R. Corder and A. Lahiri: Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol., 55(19), 2049-61 (2010)
94. U. Naumann, W. Wick, R. Beschorner, R. Meyermann and M. Weller: Expression and functional activity of osteoprotegerin in human malignant gliomas. Acta Neuropathol, 107(1), 17-22 (2004)
95. L. C. Hofbauer, S. Cepok and B. Hemmer: Osteoprotegerin is highly expressed in the spinal cord and cerebrospinal fluid. Acta Neuropatho, 107(6), 575-7 (2004)
96. E. Emanuele, E. Peros, G. A. Scioli, A. D'Angelo, C. Olivieri, L. Montagna and D. Geroldi: Plasma osteoprotegerin as a biochemical marker for vascular dementia and Alzheimer's disease. Int J Mol Med, 13(6), 849-53 (2004)
97. A. L. Jefferson, J. M. Massaro, P. A. Wolf, S. Seshadri, R. Au, R. S. Vasan, M. G. Larson, J. B. Meigs, J. F. jr. Keaney, I. Lipinska, S. Kathiresan, E. J. Benjamin and C. DeCarli: Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. Neurology, 68(13), 1032-8 (2007)
98. C. Luckhaus, B. Mahabadi, B. Grass-Kapanke, M. Jänner, H. Willenberg, M. Jäger, T. Supprian and K. Fehsel: Blood biomarkers of osteoporosis in mild cognitive impairment and Alzheimer's disease. J Neural Transm, 116(7), 905-11 (2009)
99. P. Mátyus, B. Dajka-Halász, A. Földi, N. Haider, D. Barlocco and K. Magyar: Semicarbazide-sensitive amine oxidase: current status and perspectives. Curr Med Chem, 11(10), 1285-98 (2004)
100. F. Boomsma, P.J. de Kam, G. Tjeerdsma, A.H. van den Meiracker and D.J. van Veldhuisen: Plasma semicarbazide-sensitive amine oxidase (SSAO) is an independent prognostic marker for mortality in chronic heart failure. Eur Heart J, 21(22), 1859-63 (2000)
101. M. Unzeta, M. Solé, M. Boada and M. Hernández: Semicarbazide-sensitive amine oxidase (SSAO) and its possible contribution to vascular damage in Alzheimer's disease. J Neural Transm, 114(6), 857-62 (2007)
102. Z.J. Jiang, J.S. Richardson and P.H. Yu: The contribution of cerebral vascular semicarbazide-sensitive amine oxidase to cerebral amyloid angiopathy in Alzheimer's disease. Neuropathol Appl Neurobiol, 34(2), 194-204 (2008)
103. J.L. Sullivan: Stored iron and vascular reactivity. Arterioscler Thromb Vasc Biol, 25, 1532-5 (2005)
104. E.S. Ford: Serum copper concentration and coronary heart disease among US adults. Am J Epidemiol, 151(12), 1182-8 (2000)
105. G.J. Brewer: Iron and copper toxicity in diseases of aging, particularly atherosclerosis and Alzheimer's disease. Exp Biol Med (Maywood), 232(2), 323-35 (2007)
106. B. Liu, A. Moloney, S. Meehan, K. Morris, S.E. Thomas, L.C. Serpell, R. Hider, S.J. Marciniak, D.A. Lomas and D.C. Crowther: Iron promotes the toxicity of amyloid {beta} peptide by impeding its ordered aggregation. J Biol Chem, 286(6), 4248-56 (2011)
107. S. Bucossi, M. Ventriglia, V. Panetta, C. Salustri, P. Pasqualetti, S. Mariani, M. Siotto, P.M. Rossini and R. Squitti: Copper in Alzheimer's disease: a meta-analysis of serum,plasma, and cerebrospinal fluid studies. J Alzheimers Dis, in press (2010)
108. M. Silvestrini, B. Gobbi, P. Pasqualetti, M. Bartolini, R. Baruffaldi, C. Lanciotti, R. Cerqua, C. Altamura, L. Provinciali and F. Vernieri: Carotid atherosclerosis and cognitive decline in patients with Alzheimer's disease. Neurobiol Aging, 30(8), 1177-83 (2009)
109. M.J. Jurasic, I.M. Popovic, S. Morovic, Z. Trkanjec, V. Seric and V. Demarin: Can beta stiffness index be proposed as risk factor for dementia. J Neurol Sci, 283(1-2), 13-6 (2009)
110. J.C. de la Torre: Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol, 3(3), 184-190 (2004)
111. R.C. Becker: Emerging paradigms, platforms, and unifying themes in biomarker science. J Am Coll Cardiol, 50(18), 1777-80 (2007)
112. F. Song, A. Poljak, G. A. Smythe and P. Sachdev: Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. Brain Res Rev, 61(2), 69-80 (2009)
113. E. Siemers, R. B. DeMattos, P. C. May and R. A. Dean: Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials. Biomark Med, 4(1), 81-9 (2010)
114. P. Schneider, H. Hampel and K. Buerger: Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. CNS Neurosci Ther, 15(4), 358-74 (2009)